www3.utsouthwestern.edu
Upcoming SlideShare
Loading in...5
×
 

Like this? Share it with your network

Share

www3.utsouthwestern.edu

on

  • 994 views

 

Statistics

Views

Total Views
994
Views on SlideShare
994
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft Word

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

www3.utsouthwestern.edu Document Transcript

  • 1. Darren Keith McGuire, MD, MHSc, FACC Assistant Professor of Medicine Associate Director, Internal Medicine Residency Training Program Associate, Donald W. Reynolds Cardiovascular Clinical Research Center Director, Parkland Hospital and Health Systems Outpatient Cardiology University of Texas Southwestern Medical Center 5323 Harry Hines Boulevard St Paul Hospital Suite HA9.133 Dallas, TX 75390-9047 Education and Training 1997-2001 Cardiology Fellowship, Duke University Medical Center Durham, North Carolina Board Certification-Cardiology 1/02 1998-2000 MHSc-Duke University Clinical Research Training Program Durham, North Carolina 1996-1997 Cardiology Research Fellowship-UT Southwestern Dallas, Texas 1993-1996 Intern/Resident-Internal Medicine; UT-Southwestern Dallas, Texas Board Certification-Internal Medicine 11/96 1989-1993 M.D. Johns Hopkins University School of Medicine Baltimore, Maryland 1985-1989 B.A.-Chemistry Hendrix College Conway, Arkansas Research Training 1998-2001 Duke Clinical Research Institute; Mentor: Christopher B. Granger Durham, NC 1996-1997 UT-Southwestern Division of Cardiology Dallas, Texas Human Physiology Lab; Mentor: Dr. Jere H. Mitchell 1988-1990 University of Arkansas Medical Sciences Campus Little Rock, Arkansas 1989, 1990- Department of Orthopedic Surgery; Mentor: Dr. James Aronson 1988-Department of Biochemistry; Mentor: Dr. Charles Liarakos 1987 Texas A&M University College Station, TX Department of Biochemistry; Mentor: Dr. John L. Hogg Professional Positions 2005-Present Ad hoc reviewer-Diabetologia 2005-Present Ad hoc reviewer-Diabetic Medicine 2005 Co-chair, Insulin Resistance, Diabetes, and Vascular Disease Symposium, World Congress on the Insulin Resistance Syndrome, November 17-19, 2005, San Francisco 2005 Faculty Moderator, 2005 AHA Scientific Sessions, November 13. 2005-Present Ad hoc reviewer-Drugs 2005-Present Editorial Board, Journal of the Cardiometabolic Syndrome 2005-Present Associate Director of the UT Southwestern Internal Medicine Residency Training Program 2005-2006 Executive Committee, Emerging Science of Lipid Management (ESLM) National CME Program 2005 Co-chair; 5th Annual Diabetes Summit at the American Heart Association, November 12; Dallas, TX 2005-Present Co-chair, Emerging Science of Lipid Management (ESLM) National CME Program- Mid-west Regional Working Group 2005-Present Ad hoc reviewer-Annals of Internal Medicine 2005-present Specialty Consultants Panel-Prescriber's Letter/Pharmacist's Letter 2004-Present Ad hoc reviewer-Journal of Diabetes and Its Complications 2004-Present Ad hoc reviewer-Journal of Investigative Medicine 2004 Co-chair; 4th Annual Diabetes Summit at the American Heart Association, November 6; New Orleans, LA 2004 Faculty Moderator, 2004 AHA Scientific Sessions 2004-Present National Co-Chair, DataWave National CME Program
  • 2. 2004-Present Mentor, Amit Khera; Donald W. Reynolds Cardiovascular Clinical Research Center at UT-Southwestern 2004-2006 UT-Southwestern Institutional Review Board Executive Committee 2004-2006 Chair, UT-Southwestern Institutional Review Board #4 2004-Present Ad hoc reviewer-Archives of Internal Medicine 2004 Faculty, Transcatheter Cardiovascular Therapeutics 2004, September 27-October 1 2004-Present Ad hoc reviewer- Diabetes & Vascular Disease Research 2004 Executive Committee, Emerging Science of Lipid Management (ESLM) National CME Program 2004-Present Ad hoc reviewer-Journal of Alternative and Complementary Medicine 2004 Ad hoc Chair; UT-Southwestern Institutional Review Board #3 2004 Chair, 53rd ACC Scientific Sessions Featured Oral Session: Acute Coronary Ischemic Syndromes: Influence of Diabetes on Prognosis; New Orleans, LA March 8, 2004 2004 Co-chair, Type 2 Diabetes, The Metabolic Syndrome and Obesity: Evolving the Paradigms, January 29-31; Tysons Corner, Virginia 2003-Present Advisory Board, MDDVD.org 2003 Co-chair; 3rd Annual Diabetes Summit at the American Heart Association, November 8; Orlando, Florida 2003-2004 Co-chair, Emerging Science of Lipid Management (ESLM) National CME Program- West Regional Working Group 2003-Present Ad hoc Guest Editor-American Heart Journal 2003-2004 UT-Southwestern Institutional Review Board #3 2003-Present Fellow, American College of Cardiology; elected 2/3/2003 2003-Present Associate Editor; Diabetes & Vascular Disease Research 2003-Present Executive Council, Founding Fellow and Trustee, International Society of Diabetes and Vascular Disease 2003-Present Ad hoc reviewer-European Heart Journal 2002-Present Ad hoc reviewer-Circulation 2002-Present Editorial Board, theheart.org 2002-Present Director, Parkland Hospital and Health Systems Outpatient Cardiology 2002-Present Ad hoc reviewer-American Journal of Physiology 2001-Present Co-mentor, Anne-Marie Svensson; Doctoral Candidate, University of Göteborg, Göteborg, Sweden 2001-Present Editorial Board, American Heart Journal 2001-Present Associate, Donald W. Reynolds Cardiovascular Clinical Research Center 2001-Present Development Consultancy Board, Sankyo Pharmaceuticals 2001 Diabetes Advisory Board, Eli Lilly & Company 1999-Present Content Consultant, theheart.org 1997-Present Ad hoc reviewer-American Heart Journal 1997-Present Ad hoc reviewer-Diabetes Care Research Support 2003-present Principal Investigator, Pom-Wonderful Study 2003-present Takeda Study 504 (PURE 2) Steering Committee 2003-2004 Principal Investigator, Takeda Study 504 (PURE 2) 2002-present Principal Investigator, DREAM study 2002-present Principal Investigator, TRANSCEND study 2002-present Principal Investigator, ONTARGET study 2001-2004 Principal Investigator-Estudios Cardiologica Latinoamericas (ECLA) Glucose-Insulin- Potassium (GIK) II Trial 2001-2004 Co-Investigator-Superior Yield of the New Strategy of Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) Trial 1999-2005 Estudios Cardiologica Latinoamericas (ECLA) Glucose-Insulin-Potassium (GIK) II Trial Steering Committee 1999-2000 BARI 2D Steering Committee 1999-2000 Co-Investigator BARI 2D Trial; Duke University Medical Center
  • 3. Grant No.: n/a Grant Title: Post-Acute Coronary Events-Therapy (PACE-Rx) Study PI: Darren K. McGuire Project period: 10/01/1999-6/30/2004 Award amount: $60,000 (unrestricted educational grant) Grantor: Pfizer pharmaceuticals Broad Goal: To evaluate the effectiveness of an algorithm-based disease management strategy applied by physician-extenders in the evidence-based management of patients following acute coronary syndromes Grant No.: n/a Grant Title: Donald W. Reynolds Cardiovascular Clinical Research Center PI: Helen Hobbs Project Period: 10/01/99-09/30/006 Current Year Annual Award Amount: $3,942,923 (direct costs) Grantor: Donald W. Reynolds Foundation Role on Project: Associate Broad Goal: To develop new measures that reduce death and disability from atherosclerotic heart disease and its major complications. Salary Support: $45,000 (salary) + fringes Grant No.: n/a Grant Title: Effects of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride PI: Darren K. McGuire Project Period: 10/01/2004-4/01/2006 Award Amount: $499,864 Grantor: GlaxoSmithKline Broad Goal: To assess the effects of the thiazolidinedione medication, rosiglitazone versus placebo on parameters of cardiovascular performance, cardiac structure and function, and myocardial triglyceride content in a 4-center randomized controlled trial. Grant No.: n/a Grant Title: Effects of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride PI: Darren K. McGuire Project Period: 10/01/2004-4/01/2006 Award Amount: $100,000 Grantor: Donald W. Reynolds Foundation Broad Goal: To assess the effects of the thiazolidinedione medication, rosiglitazone versus placebo on parameters of cardiovascular performance, cardiac structure and function, and myocardial triglyceride content in a 4-center randomized controlled trial. Grant No.: n/a Grant Title: Effects of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride PI: Darren K. McGuire Project Period: 10/01/2004-4/01/2006 Award Amount: $50,000 Grantor: Biosite, Inc. Broad Goal: To assess the effects of the thiazolidinedione medication, rosiglitazone versus placebo on parameters of cardiovascular performance, cardiac structure and function, and myocardial triglyceride content in a 4-center randomized controlled trial.
  • 4. Honors/Awards 2005 Nominee, ACC Douglas P. Zipes Distinguished Young Scientist Award 2005-present Alumni Board, Hendrix College, Conway, Arkansas 2000-2001 Outstanding Clinical Research Fellow, Duke University Cardiology 1999-2000 Chief Fellow, Duke Clinical Research Institute 1993-current Alpha Omega Alpha Medical Honor Society 1989 Graduated Summa Cum Laude with Honors and Distinction in Chemistry, Hendrix College 1987.1989 Arkansas National Advisory Board Scholar 1985.1989Arkansas Governor’s Scholar 1988 Arkansas Rhode’s Scholarship Nominee Invited Lectures 2005 University of Texas Southwestern Medical Center Internal Medicine Grand Rounds, "Cardiovascular Considerations of the Thiazolidinediones: Update on the Evidence", November 10. 2005 Oklahoma University Health Science Center Internal Medicine Grand Rounds, "Cardiovascular Considerations of the Thiazolidinediones", October 19 2005 Louisiana State University Ark-La-Tex Annual CME Symposium; "Diabetes and Cardiovascular Disease: What's the Evidence?", August 20. 2005 Duke University Medical Center joint Cardiology/Endocrinology Grand Rounds; "Diabetes and Cardiovascular Disease: What's the Evidence?", August 15. 2005 Faculty, Emory University ESCAPE CME Program; Amelia Island, FL; June 13. 2005 Faculty, Johns Hopkins CME@Sea Program; Ft. Lauderdale, FL; June 4-11. 2005 "Diabetes and Cardiovascular Disease: What is the Evidence?", Methodist Hospital Dallas Internal Medicine Grand Rounds, May 20. 2005 "IRB Committee Management and Maintenance", UT Southwestern Medical Center Symposium on IRB Best Practices, May 11-12, 2005 2005 "Diabetes and Cardiovascular Disease: What is the Evidence?", Oklahoma University Health Science Center Cardiology Grand Rounds, April 29. 2005 "Metabolic Syndrome: Can Biomarkers Help?", UCSD Symposium on Biomarkers in Heart Disease, La Jolla, CA, March 26. 2005 "The Diabetic Patient with Multivessel Coronary Disease", Am Coll Cardiol Annual Scientific Sessions, March 9. 2005 Cardiovascular Risks in Diabetes: Find 'em and Fix 'em", Diabetes 2005 Conference, Arlington,TX, February 19. 2005 "Diabetes and Cardiovascular Disease: What's the Evidence?", Internal Medicine Grand Rounds, Presbyterian Hospital Dallas, January 12. 2004 "Insulin in Acute MI"; CME Satellite session of AHA, November 14. 2004 "Critical Management Decisions in the ACS Patient with Diabetes"; CME Cybersession; theheart.org; August 16. 2004 "The Diabetic Epidemic: Epidemiologic and therapeutic implications for the interventional cardiologist." Transcatheter Cardiovascular Therapeutics 2004 , September 27 2004 "Pharmacologic modification of cardiovascular risk in diabetes: Glucose control and beyond." Transcatheter Cardiovascular Therapeutics 2004 , September 29 2004 University of Texas Annual Chancellor's Council Meeting: "Emerging Concepts of Lipid Therapy: How low can we go?"; Austin, Texas; April 30. 2004 Lakewood Community Hospital Internal Medicine Grand Rounds: “Thiazolidinediones: Cardiovascular Friend or Foe,” Lakewood, Ohio; April 21. 2004 "Glucose and Insulin in Acute MI: Where are we now?"; UT Southwestern Medical Center Cardiology Clinical Conference, March 11, 2004. 2004 "Emerging Markers of Atherogenic Risk-The Old and the New: Lipid Markers"; American College of Cardiology 53rd Annual Scientific Sessions, New Orleans, LA; March 10, 2004.
  • 5. 2003 Methodist Medical Center Internal Medicine Grand Rounds: “Thiazolidinediones: Cardiovascular Friend or Foe,” October 10. 2003 Faculty, “CME on the Plaza: Diabetes and Vascular Disease Update”, “Insulin Resistance-The Metabolic Syndrome,” Saint Luke’s Hospital of Kansas City, September 20. 2003 Baylor University Medical Center, Cardiology Grand Rounds: “Thiazolidinediones: Cardiovascular Friend or Foe,” August 22. 2003 University of Texas-Southwestern Department of Dermatology: “Rules and Regulations of Human Investigation: Learning the Alphabet”; February 17 2002 Visiting Lecturer, University of Texas Health Science Center Division of Cardiology: Cardiac Metabolism Seminar-“Thiazolidinediones: Cardiovascular Friend or Foe”; December 19 2002 St. Paul University Hospital Internal Medicine Conference, Dallas, Texas: “Thiazolidinediones: Cardiovascular Friend or Foe”; December 18 2002 Guest Commentator: “AHA Day in Review: Dyslipidemia” CyberSession; American Heart Association Scientific Sessions, Nov 18, 19; on theheart.org 2002 Faculty, 2nd Annual Diabetes Summit: Linking Science to Medicine: “Type 2 Diabetes Mellitus: The Modern-day Pandemic”, November 16 2002 University of Texas-Southwestern Medical Center Congestive Heart Failure Club, Dallas, TX: “Cardiovascular Pleiotropy of Thiazolidinedione Medications,” November 7 2002 University of Texas-Southwestern Medical Center Internal Medicine Grand Rounds, Dallas, Texas: “Thiazolidinediones: Cardiovascular friend or foe?” October 3 2002 Texas Tech University Fall Medical Symposium, Amarillo, Texas: “Reducing cardiovascular risk among patients with diabetes.” September 14 2002 Herzcentrum Ludwigshafen, Ludwigshafen Germany Division of Cardiology Grand Rounds: “Reducing cardiovascular risk among patients with diabetes.” August 27 2002 Takeda Pharmaceuticals Scientific, Medical, and Research Topics (SMART) series: “Diabetes and Cardiovascular Disease”, August 26 2002 University of Texas-Southwestern Medical Center Donald W. Reynolds Cardiovascular Research Center Works-In-Progress Seminar: “Rules and Regulations of Human Investigation: Learning the Alphabet.” July 12 2002 University of Texas-Southwestern Medical Center Endocrinology Grand Rounds: “Glucose-Insulin-Potassium Therapy for Acute Myocardial Infarction: What goes around comes around.” April 24 2002 Faculty, The Metabolic Syndrome of Cardiovascular Risk and Insulin Resistance, Washington, DC; April 18-20 2002 Faculty, Eli Lilly Global Medical Conference: Diabetes and Cardiovascular Disease, Indianapolis, IN; March 14-15 2002 Faculty, Diabetes and Cardiovascular Disease: The role of Glycoprotein IIb/IIIa Inhibitors, Atlanta, GA; February 6 2001 University of Texas-Southwestern Medical Center Cardiology Grand Rounds: “Glucose-Insulin-Potassium Therapy for Acute Myocardial Infarction: What goes around comes around.” December 14 2001 Faculty, Association of Diabetes Educators of Utah Annual Session, Salt Lake City, UT; October 19 1999 Faculty, Diabetes Update ‘99, May 3-5; Indiana University: “Diabetes and Cardiovascular Disease” Teaching Activities 2004-Present Clinical Research Seminar for Summer Research Interns at UT Southwestern Medical Center: "Introduction to Statistics". 2003-Present Lecture Series for UT Southwestern Internal Medicine Housestaff: Reading and Interpreting Medical Literature 2003-Present Instructor, UT-Southwestern School of Allied Health Sciences “Health Care Research” course
  • 6. 2001-Present Faculty, Internal Medicine Subinterns' Morning Report 2001-Present Co-Director, UT-Southwestern Internal Medicine Residency Journal Club at Parkland 2001-Present Course facilitator, UT-Southwestern Medical School “Clinical Ethics in Medicine” course 2002-Present UT-Southwestern Division of Cardiology, Didactic Lecture Series for Fellows Diabetes and Cardiovascular Disease Introduction to Statistics Trial Design-Power and Sample Size Considerations 2002-Present Faculty, UT-Southwestern School of Allied Health Sciences-Physical Therapy Course on Pathophysiology 2002-Present Faculty, UT-Southwestern School of Allied Health Sciences-Physician Assistant Course on Clinical Pharmacology Bibliography Original research: Liarakos CD, Maddox RP, Hilscher KA, Bishop JR 3d, McGuire DK, Kopper RA. Determination of secondary structure in the initiation region of ovalbumin mRNA. Nucleic Acids Res 1988; 16: 11249-65. McGuire DK, Emanuelsson H, Granger CB, Ohman EM, Moliterno DJ, White HD, Ardissino D, Box JW, Califf RM, Topol EJ, for the GUSTO IIb Investigators. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes: Findings from the GUSTO IIb study. Eur Heart J, 2000; 21:1750-8. The 2nd SYMPHONY Investigators. A randomized comparison of sibrafiban plus aspirin, aspirin alone, and sibrafiban alone for prevention of ischemic events after acute coronary syndromes. Circ 2001; 103:1727-33. McGuire DK, Levine BD, Williamson JW, Snell PG, Blomqvist CG, Saltin B, Mitchell JH. A 30-year follow-up of the Dallas bed rest and training study: Effect of age on the cardiovascular response to exercise. Circ 2001;104:1350 -7. McGuire DK, Levine BD, Williamson JW, Snell PG, Blomqvist CG, Saltin B, Mitchell JH. A 30-year follow-up of the Dallas bed rest and training study: Effect of age on the cardiovascular adaptation to exercise training. Circ 2001; 104:1358-66. Labinaz M, Madan M, O’Shea JC, Kilaru R, Chin W, Pieper K, McGuire DK, Saucedo J, Talley JD, Liu H, Kitt MM, Califf RM, Tcheng JE, for the ESPRIT Investigators. One-year Outcomes of Diabetic Patients Following Coronary Stenting:Results from the Enhanced Suppression of the Platelet IIb/IIIa Receptor withIntegrilin Therapy (ESPRIT) Trial. Am J Cardiol 2002; 90:585-590. Newby LK, Kristinsson A, Bhapkar MV, Aylward PE, Dimas AP, Klein WW, McGuire DK, Moliterno DJ, Verheugt FWA, Weaver WD, Califf RM, for the SYMPHONY and 2nd SYMPHONY Investigators. Early statin use and outcomes in patients with acute coronary syndromes. JAMA 2002; 287:3087-3095. McGuire DK, Anstrom KA, Peterson ED. The influence of the BARI NHLBI diabetic clinical alert on practice patterns: Results from the National Cardiovascular Network database. Circulation 2003; 107:1864-1870. Cheng YJ, Church TS, Kimball TE, Nichaman MZ, Levine BD, McGuire DK, Blair SN. Coronary artery calcium detected by electron beam tomography and its association with coronary heart disease in 17,967 women and men. American Journal of Cardiology 2003; 92:498-503. McGuire DK, Newby LK, Bhapkar MV, Moliterno DJ, Hochman JS, Klein W, Weaver WD, Pfisterer M, Dimas A, Corbalan R, Granger CB, Van de Werf F, Topol EJ, Califf RM, for the SYMPHONY and 2nd SYMPHONY Investigators. Influence of Diabetes Mellitus and Glycemic Control Strategies on Clinical Outcomes After Acute Coronary Syndromes: Findings from the SYMPHONY and 2ND SYMPHONY Studies. Am Heart J 2004; 147: 246-52. ElMunzer BJ, Sallach SM, McGuire DK. Case Report: Cardiac Chagas’ Disease masquerading as an acute MI. Cardiology in Review 2004;12: 69-72. McCollum DL, Greene J, McGuire DK. Severe bradycardia after initiation of bupropion therapy: A possible drug-drug interaction with metoprolol. Cardiovascular Drugs and Therapy, 2004; 18:329-30.
  • 7. Aslam MK, Gnaim C, Kutnick J, Kowal RC, McGuire DK. Syndrome of inappropriate anti-diuretic hormone secretion induced by amiodarone therapy. PACE 2004; 27:831-832. Jain T, Peshock R, McGuire DK, Willet D, Vega G, Guerra R, Yu Z, Hobbs HH, MD, Grundy SM, and the Dallas Heart Study Investigators. African Americans and Caucasians have a Similar Prevalence of Coronary Calcium as Detected By Electron Beam Computer Tomography. J Am Coll Cardiol 2004; 44: 1011-1017. Asher CR, Moliterno DJ, Bhapkar MV, McGuire DK, Rao SV, Holmes DR, Newby LK, Bates ER, Topol EJ, for the SYMPHONY and 2nd SYMPHONY Investigators. Association of race with complications and prognosis following acute coronary syndromes. Am J Cardiol 2004;94:792-794. Deo R, Khera A, McGuire DK, Murphy S, Pardo Meo Neto J, Morrow DA, de Lemos JA. Association Between Plasma Levels of Monocyte Chemoattractant Protein-1, Traditional Cardiovascular Risk Factors and Subclinical Atherosclerosis. J Am Coll Cardiol, 2004. 1812-1818. Addo T, Keeley EC, Cigarroa JE, Lange RA, deLemos JA, Dobbins RL, McGuire DK. The Effect of Glucose-Insulin-Potassium Infusion on Plasma Free Fatty Acid Concentrations in the Setting of Primary Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction. Am J Cardiol 2004; 94: 1288-1289. Svensson AM, Abrahamsson P, McGuire DK, Dellborg M. Influence of Diabetes on Outcome among Unselected Patients with Acute Coronary Events: A 10-year experience with 4341 patients. Scand Cardiovasc J 2004; 38:229-34. Svensson AM, McGuire DK, Abrahamsson P, Dellborg M. Glycometabolic state at admission and during hospitalization: Important Risk Marker of Mortality in Diabetes Patients with Acute Coronary Events: a 10 year experience . European Heart J, 2005; 38: 229-34. Sánchez CD, Newby LK, McGuire DK, Hasselblad V, Feinglos MN, Ohman EM. Diabetes-related knowledge is not associated with measures of risk factor control or cardiac outcomes in patients with diabetes and acute coronary syndromes. Am J Cardiol 2005; 95: 1290-94. Sims JB, de Lemos JA, Maewal P, Warner JJ, Peterson GE, McGuire DK. Urinary Tract Infection in Patients with Acute Coronary Syndrome: A Potential Systemic Inflammatory Connection. Am Heart J 2005; 149: 1062-5. Khera A, McGuire DK, Murphy SA, Stanek G, Das S, Vongpatanasin W, Wians F, Grundy S, de Lemos, JA. Race and Sex Differences in C-reactive Protein Levels. J Am Coll Cardiol, 2005; 46: 464-469. Eisenstein EL, McGuire DK, Bhapkar MV, Kristinsson A, Hochman JS, Kong DF, Topol EJ, Califf RM, Van de Werf F, Newby LK, for the SYMPHONY and 2nd SYMPHONY Investigators. Body Mass Index (BMI) and Intermediate-Term Clinical Outcomes after Acute Coronary Syndromes: Observations from the SYMPHONY and 2nd SYMPHONY Trials. Am J Med 2005; 118/9:981-990. Dorfman T, Canales J, Farukhi I, McGuire DK. Sarcoidosis Masquerading as an Acute Coronary Syndrome. Cardiology in Review 2005; 13:256-259. Abdullah SM, Khera A, Das SR, Stanek HG, Canham RM, Chung AK, Morrow DA, Drazner MH, McGuire DK, de Lemos JA. Relation of Coronary Atherosclerosis Determined by Electron Beam Computed Tomography and Plasma Levels of N-terminal Pro-Brain Natriuretic Peptide in a Multiethnic Population-Based Sample (The Dallas Heart Study). Am J Cardiol 2005. 96: 1284-1289. de Lemos JA, Zirlik A, Schönbeck U, Varo N, Murphy SA, Khera A, McGuire DK, Stanek G, Lo HS, Nuzzo R, Morrow DA; Peshock R, Libby P. Associations Between Soluble CD40 Ligand, Atherosclerosis Risk Factors, and Subclinical Atherosclerosis: Results from the Dallas Heart Study. Art Thromb Vasc Biol 2005; 25: 2192-2196. Frazier CG, Shah SH, Newby LK, Bhapkar MV, McGuire DK, Weaver WD, Kristinsson A, Aylward PE, Klein WW, Sadowksi Z, Armstrong PW, for the SYMPHONY and 2nd SYMPHONY Investigators. Prevalence and Management of Hypertension in Acute Coronary Syndrome Patients Varies by Sex. Am Heart J 2005; 150: 1260-1267. Das SR, Vaeth PAC, Stanek HG, de Lemos JA, Dobbins RL, McGuire DK. Under-diagnosis, Increased Coronary Calcium and Sub-optimal Cardiovascular Risk Modification Associated with Diabetes Mellitus in Dallas County:Observations from the Dallas Heart Study. Am Heart J 2005; In Press
  • 8. Khera A, de Lemos JA, Peshock RM, Lo H, Stanek HG, Murphy SA, Wians FH, Grundy SM, McGuire DK. Lack of an Independent Association Between C-Reactive Protein and Subclinical Atherosclerosis: The Dallas Heart Study. Circulation 2005; In Press Church TS, Levine BD, McGuire DK, LaMonte M, Fitzgerald S, Cheng YJ, Kimball TE, Blair SN, Gibbons LW, Nichaman MZ. Coronary artery calcium score and risk of coronary heart disease events. In review. Yan RT, Yan AT, Tan M, McGuire DK, Leiter L, Fitchett DH, Lauzon C, Lai K, Chow CM, Langer A, Goodman SG; for the Canadian Acute Coronary Syndrome Registry Investigators. Underutilization of Evidence-Based Treatment Partly Explains the Worse Clinical Outcome in Diabetic Patients with Acute Coronary Syndromes. In Review Cho MN, Mehta SK, Matulevicius S, Weinstein D, Wait MA, McGuire DK. Differentiating True versus Pseudo Left Ventricular Aneurysm: A Case Report and Review of Diagnostic Strategies. In Review Invited reviews and Book chapters: Califf RM, McGuire DK, Feinglos MA. Caring for the patient with diabetes and myocardial infarction. In Califf, RM, ed. New Standards of AMI Care. Part V: Reperfusion of Special Populations. New York: Exerpta Medica, Inc, 1998:13-25. McGuire DK, Granger CB, Califf RM, editors. Diabetes and Cardiovascular Disease: Current opinions and future directions-Proceedings of a symposium. Am Heart J 1999; 138: S327-S416. McGuire DK, Califf RM. Diabetes and Cardiovascular Disease: Current opinions and future directions- Introduction. Am Heart J 1999; 138: S327-329. Abraira C, McGuire DK. Intensive insulin therapy in patients with type 2 diabetes: Implications of the Veterans Affairs (VACSDM) feasibility trial. Am Heart J 1999; 138: S360-S365. McGuire DK, Granger CB. Diabetes and ischemic heart disease. Am Heart J 1999; 138: S366-S375. Malmberg K, McGuire DK. Diabetes and acute myocardial infarction: The role of insulin therapy. Am Heart J 1999; 138: S381-S386. McGuire DK. Diabetes and Cardiovascular Disease: Evidence-Based Therapy. Resident and Staff Physician 2000; 46:19-31. Diaz R, McGuire DK. Optimal dosage of insulin and glucose in Glucose-Insulin-Potassium treatment of acute myocardial infarction remains to be established. Circ 1999; 100: e106-e107. McGuire DK, Hudson MP, East MA, Dyke CD, Battle J, Bahit MC, Al-Khatib SM, Alexander JH. AHJ at the Meetings: Highlights from the American Heart Association 72nd Scientific Sessions November 6 to 10, 1999. Am Heart J 2000; 139:359-370. McGuire, DK. The Influence of Proteinuria on Long-term Outcome Among Patients with Diabetes: The evidence continues to accumulate. Am Heart J 2000; 139:934-935. McGuire DK, Newby LK. Oral glycoprotein IIb/IIIa antagonists: New insights from the SYMPHONY Trial. Journal of Thrombosis and Thrombolysis 2000;10:111-120. McGuire DK, O’Shea JC, Dyke CK, Kandzari D, East MA, Tolleson TR. Highlights from the American College of Cardiology 49th Annual Scientific Sessions: March 12 to 15, 2000. Am Heart J 2000; 140:181-188. Newby LK, McGuire DK. Oral platelet glycoprotein IIb/IIIa inhibition. Curr Cardiol Rep 2000; 2:372-377. McGuire DK, O’Shea JC, Dyke CK, Velazquez EJ, Hudson MP. Highlights from the XXII Congress of the European Society of Cardiology: August 26 to 30, 2000. Am Heart J 2001; 141:164-172. Sanchez CD, McGuire DK. Diabetes mellitus and clinical outcomes following acute coronary syndromes. Cardiology Reviews 2001;18:10-14. O'Shea JC, Bahit C, Tolleson TR, Cabell C, Dyke CK, Kaul A, McGuire DK, East MA. Highlights from the American Heart Association Annual Scientific Sessions 2000: November 12 to 15, 2000. Am Heart J 2001; 141: 306-318. Bahit MC, Cabell CH, Dyke CK, Felker GM, Kaul P, McGuire DK, Reddan D, East M. Highlights from the American College of Cardiology 49th Annual Scientific Sessions: March 18 to 21, 2001. Am Heart J 2001; 142:363-74. Patel MR, McGuire DK. Pounds of prevention: Obesity therapy. Am Heart J 2001; 142:388-90.
  • 9. Brosnan R, McGuire DK. Influencing CV results among type 2 diabetics. Today in Cardiology 2002; 5:4-6. Lincoff AM, Engel SS, Bhatt DL, Goldschmidt P, McGuire DK, Marso SP. Diabetes and cardiovascular disease: The role of the glycoprotein IIb/IIIa inhibitors. New York: AM Medica Communications, 2002. McGuire DK. Type 2 Diabetes and Ischemic Heart Disease: A CME Monograph.Toronto: Conceptis Communications, 2002. McGuire DK, Marso SP, Bhatt DL. The Experts Speak Out: Modifying the Risk for Diabetic Patients Undergoing PCI. CME Cybersession, Conceptis Technologies, June 2002. de Lemos JA, McGuire DK. Aspirin, clopidogrel, or both for secondary prevention of coronary disease (Letter). N Eng J Med 2003; 348: 560-3. Abedin M, McGuire DK. Don’t miss this opportunity: Diagnosing diabetes. Am Heart J 2003; 145:195-7. de Lemos JA, McGuire DK, Drazner MH. B-type Natriuretic Peptide (BNP) in Cardiovascular Disease. Lancet 2003; 362: 316-22. Rao SV, McGuire DK. Epidemiology of Diabetes Mellitus and Cardiovascular Disease in The Textbook of Diabetes Mellitus and Cardiovascular Disease. David Stern and Steven P. Marso, editors. Lippincott Williams & Wilkins, Philadelphia, 2003. Keebler ME, McGuire DK. Subclinical Diabetes: Is it really sub-clinical? Am Heart J 2003;146:210-212 de Lemos JA, McGuire DK. Lipids and diabetes: potential therapeutic synergies. Lipid Letter 2003; 2:1-6. McGuire DK, Newby LK, Biswas M, Hochman JS. The Elderly, Woman, and Patient with Diabetes in Acute Coronary Syndromes: A Companion to Braunwald’s Heart Disease. Pierre Theroux, Editor. Harcourt Health Sciences, 2003. Drazner MH, McGuire DK, de Lemos JA. Nesiritide in acute heart failure (letter). Lancet 2003; 362: 998-999. Petersen JL, McGuire DK, Harrington RA. Advances and continued controversy in revascularization for coronary artery disease in patients with diabetes mellitus. Current Diabetes Reports 2003; 3:351-355. McGuire DK, Rao SV. Epidemiology of Diabetes and Cardiovascular Disease in The Handbook of Diabetes and Cardiovascular Disease. Steven P. Marso, editor. Remedica Publishing, London UK, 2003. Martin JL, McGuire DK. Influence of BARI on revascularization in patients with diabetes. Cardiology Reviews 2004; 21: 14-18. Martin JL, McGuire DK. Case Report: Coronary artery bypass graft surgery for a diabetic patient. Cardiology Reviews 2004; 21: 19. Berry J, Keebler ME, McGuire DK. Diabetes and Cardiovascular Disease: Pandora´s Box has been Opened. Herz 2004; 29: 456-462. Gnaim CI, McGuire DK. Glucose-Insulin-Potassium Therapy for Acute Myocardial Infarction: What goes around comes around. Am Heart J 2004; 148:924-930. McGuire DK, Newby LK. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. (Letter) Am Heart J 2004; 148:e28. Patel CB, Wyne K, McGuire DK. Thiazolidinediones, Peripheral Edema and CHF: What is the evidence? Diabetes and Vascular Disease Research, 2005; 2: 61-66. Khera A, McGuire DK. Management of Diabetic Dyslipidemia: Need for Reappraisal of the Goals. Am J of Cardiovasacular Drugs, 2005; 2: 83-91. McGuire DK, Khera A, de Lemos JA. Treating the patient with diabetes and coronary disease. LipidLetter 2004; In Press. Petersen JL, McGuire DK. Implications for Cardiovascular Risk and Management of Impaired Glucose Tolerance and Impaired Fasting Glucose. J Diabetes Vasc Dis 2005; 2: 9-15. McGuire DK, Rutherford JD. Risk factors: Diabetes and CHD. ACC SAP IV, 2004. In Press Patel M, McGuire DK. How Aggressive Should Lipid Lowering Be Among Patients With Acute Coronary Syndromes? Current Cardiology Reports 2005; 7: 283-287. Winterfield JR, Ferranini E, McGuire DK. ACE inhibitors for the Prevention of Diabetes Mellitus: Fact or fiction? In Review Patel CB, de Lemos JA, Wyne K, McGuire DK. Thiazolidinediones and Atherosclerosis: Pleiotropic effects of PPARγ agonism. In Review.
  • 10. Papers in Preparation: Petersen JL, Nelson CL, Peterson ED, Granger CB, McGuire DK, Harrington RA. Impaired fasting glucose, diabetes mellitus, and the risk of adverse cardiac events for patients in the Duke Database for Cardiovascular Disease. In preparation McGuire DK, Khera A, Keebler ME, de Lemos JA, Peterson ED, Warner JJ, Parsons LS, Rogers WJ, Canto JG, for the National Registry of Myocardial Infarctions Investigators. Women with Diabetes Mellitus Have the Greatest Reduction in MI Mortality Over the Past Decade: Evaluation of 1,428,596 Patients Enrolled in the National Registry of Myocardial Infarction (NRMI) 2, 3, & 4 from 1994-2002. In Preparation Donahue MP, Felker GM, McGuire DK, Shaw LK, O’Connor CM. Diabetic Cardiomyopathy: Evidence of Diabetes’s Negative Impact on Survival of Regardless of Heart Failure Etiology. In Preparation Patel P, McGuire DK, Hussain T, Larsen R, Sugarman J. Physician Remuneration for Participation in Clinical Trials: Under the Public Looking Glass. In preparation Abdullah SM, Khera A, Das SR, Stanek HG, Canham RM, Chung AK, Drazner MH, McGuire DK, de Lemos JA. The Association of Plasma N-terminal B-type Natriuretic Peptides and Coronary Atherosclerosis. In preparation
  • 11. Abstracts: Liarakos CD, McGuire DK, Edmondson RG, Kopper RA. Ovalbumin mRNA structure in vivo. Am Soc Cellular Biol Abstracts 1988; 107:87A. McGuire DK, Liarakos CD, Kopper RA. Characterization of Secondary Structure in Hen Ovalbumin mRNA. EUREKA Third National Conference on Undergraduate Research, April 1989; San Antonio, Texas. (abstract) McGuire DK, Emanuelsson H, Granger CB, White HD. Diabetes mellitus is associated with worse clinical outcomes across the spectrum of acute coronary syndromes: Results from GUSTO IIb. Circ 1999; 100: I-432 (abstract). Peterson ED, Anstrom, KA, McGuire DK. The influence of the BARI diabetic treatment alert on revascularization selection patterns: The NCN results. J Am Coll Cardiol 2000; 35(suppl A): 544A. (abstract) McGuire DK, Roe MT, Bastos EM, Joski PJ, Harrington RA, Simoons ML, White HD. The Frequency of Ace Inhibitor Use Following Acute Coronary Syndromes Doubled over the Past Decade, but Remains Less Than Half of Ideal-Results from GUSTO and Pursuit Trials. Circ 2000; 102 (supp II): II-II-436 (abstract). Labinaz M, Madan M, McGuire DK, Batchelor W, Saucedo J, Pacchiana C, Kitt M, O'shea JC, Talley DJ, Liu H, Timmis S, Tcheng JE. Effect of Eptifibatide, a Glycoprotein IIb/IIIa Antagonist, Among Diabetic Patients following Coronary Stenting. Circ 2000; 102 (supp II): II-665 (abstract). McGuire DK, Newby LK, Bhapkar MV, Moliterno DJ, Ohman EM, Dougherty FC, Harrington RA, White HD, van de Werf F, Califf RM, Topol EJ, for the SYMPHONY Investigators. Diabetes doubles the risk of death among patients presenting with acute coronary syndromes: Insight from SYMPHONY, a large international trial. J Am Coll Cardiol 2001; 37(suppl A): 372A. (abstract) Mahaffey KW, Connolly PA, Sparapani R, Berdan LG, Kleiman NS, Fasteson D, Dyke CB, Bahit MC, McGuireDK, Roe MT, Newby LK, Califf RM, Topol EJ, Harrington RA. Site investigators do not accurately report myocardial infarction events: Results of event adjudication by a clinical events committee in the PARAGON-B trial. J Am Coll Cardiol 2001; 37(suppl A): 376A. (abstract) Sanchez CD, McGuire DK, Hasselblad V, Ohman EM Feinglos MN. Achieving Therapeutic Targets among Patients with Diabetes and Acute Coronary Syndromes: The Influence of Diabetes- Related Knowledge. ADA 2001 Sanchez CD, McGuire DK, Hasselblad V, Ohman EM, Feinglos MN. How are We Doing? Achievement of Therapeutic Targets in Patients with Diabetes and Acute Coronary Syndromes. ADA 2001 McGuire DK, Kristinsson A, Bhapkar MV, Aylward PE, Verheugt FWA, Weaver WD, Moliterno DJ, Newby LK. Early statin use after acute coronary syndromes (ACS) and outcomes at 90-days. Circ 2001; 104: 343 (abstract). Moliterno DJ, Asher CA, Bhapkar MV, McGuire DK, East MA, Newby LK. Increased risk of ischemic and hemorrhagic events among black patients receiving oral GP IIb/IIIa inhibitors: 1st and 2nd SYMPHONY trials. Circ 2001; 104: 779 (abstract). McGuire DK, Rao SV, Joski P, Barsness GW, Peterson ED, Jollis JG, Feinglos MN,. Granger CB. Diabetes is Associated with a Higher Risk of Death than is Prior Myocardial Infarction in the Setting of Coronary Disease: Results from the Duke Cardiovascular Database. J Am Coll Cardiol 2002;39:329A.(abstract) Sanchez CD, McGuire DK, Feinglos MN, Hasselblad V, Newby LK, Ohman EM. Diabetes-Related Knowledge Is Not Associated With Measures of Risk Factor Control in Patients With Diabetes and Acute Coronary Syndromes. J Am Coll Cardiol 2002;39:443A.(abstract) Eisenstein EL, McGuire DK, Bhapkar MV, Kristinsson A, Hochman JS, Kong DF, Topol EJ, Califf RM, Van de Werf F, Newby LK. Moderate Obesity Is Associated With Better Intermediate-Term Survival In Acute Coronary Syndromes: Results From The SYMPHONY and 2nd SYMPHONY Clinical Trials. J Am Coll Cardiol 2003; 41:387A. (abstract) Al-Khatib SM, Bhapkar MV, Klein W, Armstrong PW, Califf RM, Kristinsson A, Van De Werf F, Topol EJ, White H, McGuire DK, Newby LK. Is lipid lowering therapy associated with a lower risk of sudden cardiac death after acute coronary syndromes? PACE 2003;26:1032. (abstract)
  • 12. McGuire DK, Vaeth PAC, Basit M, Dobbins RL. Prevalence and predictors of diabetes-diagnosed and undiagnosed-in Dallas County. Donald W. Reynolds Cardiovascular Clinical Research Centers Symposium; Stanford University, May 19, 2003. Svensson AM, Abrahamsson P, McGuire DK, Dellborg M. Less aggressive treatment of Diabetic Patients with Unstable Coronary Syndromes; 2003 European Society of Cardiology. Svensson AM, Abrahamsson P, McGuire DK, Dellborg M. Diabetes Doubles Mortality Among Patients with Unstable Coronary Syndromes; 2003 European Society of Cardiology. Svensson AM, Abrahamsson P, McGuire DK, Dellborg M. The influence of diabetes on long-term mortality following unstable coronary syndromes-under treatment may contribute to worse outcomes. Circ 2003; 108: IV-745 (abstract). Newby LK, Bhapkar MV, Weaver WD, Kristinsson A, Aylward PE, Prescott M, Granasakthy A, McGuire DK. Prevalence and management of hypertension in acute coronary syndrome patients varies by sex. Circ 2003; 108: IV-632 (abstract). Addo T, Keeley EC, de Lemos JA, Dobbins RL, Baker S, Shay DR, Lange RA, Cigarroa JE, McGuire DK. Suppression of circulating free fatty acids (FFAs) associated with Glucose-Insulin- Potassium (GIK) Infusion in the setting of Primary Angioplasty for Acute Myocardial Infarction (MI). Circ 2003; 108: IV-673 (abstract). Sims JB, de Lemos JA, Maewal P, Yettman V, Warner JJ, McGuire DK. Urinary Tract Infection in Patients with Acute Coronary Syndromes: A Potential Systemic Inflammatory Connection. Young Investigators Molecular Cardiology Forum- UT Southwestern Medical Center Oct 2003 Khera A, McGuire DK, Abedin M, de Lemos JA. Risk Factors for Premature Subclinical Atherosclerosis- Results from the Dallas Heart Study- Young Investigators Molecular Cardiology Forum- UT Southwestern Medical Center Oct 2003 Khera A, de Lemos JA, Abedin M, McGuire DK. Association of Family History with Subclinical Atherosclerosis in Young Subjects- Young Investigators Molecular Cardiology Forum- UT Southwestern Medical Center Oct 2003 Sims JB, de Lemos JA, Maewal P, Yettman V, Warner JJ, McGuire DK. Urinary Tract Infection in Patients with Acute Coronary Syndromes: A Potential Systemic Inflammatory Connection. J Am Coll Cardiol 2004; 43 (suppl 5): 1A. McGuire DK, Khera A, de Lemos JA, Peterson ED, Warner JJ, Parsons LS, Rogers WJ, Canto JG, for the National Registry of Myocardial Infarctions Investigators. Women with Diabetes Mellitus Have the Greatest Reduction in MI Mortality Over the Past Decade: Evaluation of 1,428,596 Patients Enrolled in the National Registry of Myocardial Infarction (NRMI) 2, 3, & 4 from 1994-2002. J Am Coll Cardiol 2004; 43 (suppl 5): 284A. Khera A, de Lemos JA, Murphy SA, McGuire DK. Relationship Between C-Reactive Protein and Subclinical Atherosclerosis: The Dallas Heart Study. Donald W. Reynolds Cardiovascular Clinical Research Centers Symposium; Annapolis, MD, May 13, 2004. Svensson AM, McGuire DK, Kirkhoff AM, Abrahamsson P, Dellborg M. Effect of Admission Glucose on Mortality in 713 Diabetes Patients with Acute Coronary Events. 2004 European Society of Cardiology Svensson AM, McGuire DK, Eriksson M, Abrahamsson P, Dellborg M. Mortality Benefit Associated with ß-blockade among 713 Consecutive Patients with Diabetes and Acute Coronary Events. 2004 European Society of Cardiology McGuire DK, Khera A, de Lemos JA, Warner JJ, Rogers WJ, Canto JG, for the National Registry of Myocardial Infarctions Investigators. Suboptimal Use of Evidenced-based Medications Prior to Myocardial Infarction Among Patients with and without Diabetes Mellitus: Observations from the National Registry of Myocardial Infarction (NRMI) 4. Circ 2004; 110 (Supp III): III-834. Das SR, Vaeth PAC, Dobbins RA, Basit M, McGuire, DK. Diabetes is Associated with Subclinical Coronary Atherosclerosis in Dallas County: Observations from the Dallas Heart Study. Circ 2004; 110 (Supp III): III-794. McGuire DK, Svensson AM, Abrahamsson P, Dellborg M. Decreased Mortality Associated with ß- blocker Use Among 713 Consecutive Patients with Diabetes and Acute Coronary Events. Circ 2004; 110 (Supp III): III-811. McGuire DK, Svensson AM, Abrahamsson P, Dellborg M. Relationship Between Admission Glucose and Mortality in 713 Diabetes Patients with Acute Coronary Events. Circ 2004; 110 (Supp III): III-812.
  • 13. Khera A, de Lemos JA, Peshock RM, Murphy SA, Wians Jr F, Grundy SM, McGuire DK. Relationship Between C-Reactive Protein and Subclinical Atherosclerosis: The Dallas Heart Study. Circ 2004; 110 (Supp III): III-790. de Lemos JA, McGuire DK, Khera A, Murphy, SA, Das S, Willett D, Peshock R, Drazner M.N-proBNP measurement as a screening test for left ventricular structural and functional abnormalities: results from the Dallas Heart Study. ACC 2005 Scientific Sessions. Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, Wians FH, Grundy SM, de Lemos JA. Race and Sex Differences in C-Reactive Protein Levels: The Dallas Heart Study. ACC 2005 Scientific Sessions. Svensson AM, McGuire DK, Abrahamsson P, Dellborg M. Hypoglycemia during hospitalization- important risk marker of mortality in diabetic patients with acute coronary events. European Society of Cardiology Annual Scientific Sessions, September 2005, Stockholm, Sweden. Khera A, Jain T, Abdullah S, McGuire DK, Wians FH, Grundy SM, de Lemos JA. Obesity modifies the relationship between C-reactive protein and coronary artery calcification. American Heart Association Scientific Sessions, November 2006, Dallas, Texas. Das SR, Drazner MH, Abdullah SM, Khera A, McGuire DK, de Lemos JA. Natriuretic peptides and renal function: Insights from the Dallas Heart Study. American Heart Association Scientific Sessions, November 2006, Dallas, Texas.